Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report

This article was originally published in The Gray Sheet

Executive Summary

A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.

Advertisement

Related Content

The Clinical Laboratory Of The Future: Can Technology Fill The Gaps?
News In Brief
CDRH’s Mansfield Addresses Upcoming Drug/Dx Co-Development Guidance
FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail
Nestle Gains GI Diagnostics For Nutritional Health Biz Via Prometheus Deal
Thermo Fisher Underscores Allergy Test Opportunity With $3.5 Bil. Phadia Deal
Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities
Personalizing Plavix: Eric Topol Champions Genotyping For Stent Patients
Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

MT030792

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel